Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Neurology · Autosomal Dominant Alzheimer Disease

Building Your Care Team: Specialists for ADAD

At a Glance

The best care team for Autosomal Dominant Alzheimer Disease (ADAD) includes a cognitive neurologist, a genetic counselor, and a neuropsychologist. Seeking care at a specialized academic center ensures access to clinical trials, advanced diagnostics, and experts in early-onset dementia.

Because Autosomal Dominant Alzheimer Disease (ADAD) is a rare, complex, and multi-generational condition, a standard primary care doctor or general neurologist may not have the specialized knowledge you need. Building your care team is about hiring the right experts to manage both the medical and emotional aspects of this journey.

An ideal care team for ADAD is multidisciplinary, meaning it brings together different types of specialists who collaborate on your care [1][2].

The Core Medical Experts

  • Behavioral or Cognitive Neurologist: This is a neurologist with extra training in dementia. For ADAD, you specifically want someone who specializes in early-onset dementia. They should be familiar with atypical symptoms like spasticity (muscle stiffness) or psychiatric changes that can appear in ADAD before memory loss [3][4].
  • Neurogeneticist or Genetic Counselor: These professionals are the “interpreters” of your DNA. A genetic counselor does more than just order a test; they help you navigate the lifelong impact of your results, assist with family planning decisions, and provide long-term empowerment for you and your family [5][6][7].
  • Neuropsychologist: These specialists use detailed tests to map your brain’s cognitive strengths and weaknesses. In ADAD, they are essential for detecting the very subtle “preclinical” changes that might show up years before others notice a problem [8][9].

Essential Support Professionals

ADAD affects more than just your memory; it impacts your career, your family, and your mental health.

  • Specialized Social Worker: A social worker can help you navigate the “non-medical” side of ADAD, such as disability insurance, legal planning, and finding local resources for younger people with dementia [1][10].
  • Therapist or Psychologist: It is highly recommended to work with a therapist who has experience with chronic illness or genetic risk. The emotional weight of knowing your genetic status or being a caregiver for a parent requires specialized support [6].
  • Occupational Therapist (OT): As the disease progresses, an OT can help you modify your home or work environment to maintain your independence for as long as possible [11].

Finding a “Center of Excellence”

The “gold standard” for ADAD care is often found at academic medical centers that are part of the Dominantly Inherited Alzheimer Network (DIAN) or are designated as Alzheimer’s Disease Research Centers (ADRCs) [12][13]. These centers are more likely to have:

  1. Specialists who understand the nuances of specific mutations (like PSEN1 vs. APP) [14].
  2. Direct access to the latest clinical trials and “NextGen” therapies [15][16].
  3. Advanced diagnostic tools like amyloid/tau PET scans and fluid biomarker testing [17][18].

Vetting Your Doctor

When you first meet a specialist, it is important to remember that you are the one doing the hiring. If a doctor focuses only on “memory loss in the elderly,” they may not be the right fit. Ensure they understand that ADAD is a distinct condition with its own unique biological timeline and symptom profile [14][19].

When interviewing a potential neurologist, ask specifically:

  • “How many cases of early-onset or genetic Alzheimer’s do you currently treat?”
  • “Are you familiar with the specific biomarker trajectories or atypical symptoms for my family’s mutation?”
  • “Do you have a pathway to refer me to DIAN or similar prevention trials?”

If their answers are vague or dismissive, it is perfectly acceptable to seek a second opinion.

Common questions in this guide

What type of neurologist is best for Autosomal Dominant Alzheimer Disease?
For ADAD, you should look for a behavioral or cognitive neurologist who specializes in early-onset dementia. They have the specific training needed to recognize and manage atypical symptoms, like muscle stiffness or psychiatric changes, that can appear before memory loss.
Why do I need a genetic counselor for ADAD?
A genetic counselor helps you understand the lifelong impact of your DNA test results. They provide essential guidance for family planning decisions, help you navigate the emotional weight of your genetic status, and offer long-term support for your entire family.
Where is the best place to get treated for ADAD?
Centers of Excellence are typically academic medical centers that participate in the Dominantly Inherited Alzheimer Network (DIAN). They offer specialized expertise in specific genetic mutations, direct access to clinical trials, and advanced diagnostic tools like PET scans.
What questions should I ask a new doctor about my ADAD diagnosis?
You should ask how many early-onset or genetic Alzheimer's patients they currently treat. It is also important to ask if they are familiar with the specific symptoms of your family's mutation and if they have a pathway to refer you to prevention trials.
How can a social worker help someone with early-onset Alzheimer's?
A specialized social worker helps you navigate the non-medical challenges of the disease. They can assist you with disability insurance, legal planning, and finding local support resources specifically designed for younger people living with dementia.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How many patients with Autosomal Dominant Alzheimer Disease (ADAD) or early-onset Alzheimer's do you currently treat?
  2. 2.Are you familiar with the specific biomarker trajectories (like p-tau217 or NfL) and atypical symptoms (like spasticity) associated with my family's mutation?
  3. 3.Is your clinic a DIAN (Dominantly Inherited Alzheimer Network) performance site, or do you have a formal referral pathway to one?
  4. 4.How do you collaborate with genetic counselors and neuropsychologists for the long-term management of my care?
  5. 5.What is your approach to managing the 'preclinical' phase of ADAD—the 10-20 years before symptoms typically begin?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Determining Possible Professionals and Respective Roles and Responsibilities for a Model Comprehensive Elder Abuse Intervention: A Delphi Consensus Survey.

    Du Mont J, Kosa D, Macdonald S, et al.

    PloS one 2015; (10(12)):e0140760 doi:10.1371/journal.pone.0140760.

    PMID: 26630030
  2. 2

    A Multidisciplinary Model of Dementia Care in an Underserved Retirement Community, Made Possible by Telemedicine.

    Tso JV, Farinpour R, Chui HC, Liu CY

    Frontiers in neurology 2016; (7()):225 doi:10.3389/fneur.2016.00225.

    PMID: 28066313
  3. 3

    Clinical characteristics and biomarker profile in early- and late-onset Alzheimer's disease: the Shanghai Memory Study.

    Wu J, Wang J, Xiao Z, et al.

    Brain communications 2025; (7(1)):fcaf015 doi:10.1093/braincomms/fcaf015.

    PMID: 39850631
  4. 4

    Comorbid neuropathology and atypical presentation of Alzheimer's disease.

    Pina-Escudero SD, La Joie R, Spina S, et al.

    Alzheimer's & dementia (Amsterdam, Netherlands) 2024; (16(3)):e12602 doi:10.1002/dad2.12602.

    PMID: 39040464
  5. 5

    A Case for Inclusion of Genetic Counselors in Cardiac Care.

    Arscott P, Caleshu C, Kotzer K, et al.

    Cardiology in review 2016; (24(2)):49-55 doi:10.1097/CRD.0000000000000081.

    PMID: 26186385
  6. 6

    Evaluating empowerment in genetic counseling using patient-reported outcomes.

    Yuen J, Lee SY, Courtney E, et al.

    Clinical genetics 2020; (97(2)):246-256 doi:10.1111/cge.13646.

    PMID: 31571202
  7. 7

    Examining the effect of patient personality types and coping styles on outcomes of genetic counseling.

    Salman A, Morris E, Inglis A, Austin J

    Journal of genetic counseling 2023; (32(1)):68-78 doi:10.1002/jgc4.1623.

    PMID: 35913178
  8. 8

    The congruency of neuropsychological and F18-FDG brain PET/CT diagnostics of Alzheimer's Disease (AD) in routine clinical practice: insights from a mixed neurological patient cohort.

    Hansen S, Keune J, Küfner K, et al.

    BMC neurology 2022; (22(1)):83 doi:10.1186/s12883-022-02614-4.

    PMID: 35264143
  9. 9

    The role of the neuropsychologist in memory clinics.

    Salvadori E, Pantoni L,

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2020; (41(6)):1483-1488 doi:10.1007/s10072-020-04253-4.

    PMID: 31950460
  10. 10

    Development of the transition-age program (TAP): Review of a pilot psychosocial multidisciplinary transition program in a Level 4 epilepsy center.

    Reger KL, Hughes-Scalise A, O'Connor MA

    Epilepsy & behavior : E&B 2018; (89()):153-158 doi:10.1016/j.yebeh.2018.10.021.

    PMID: 30415138
  11. 11

    Assessment and management of cognitive problems in people with multiple sclerosis: A National Survey of Clinical Practice.

    Klein OA, das Nair R, Ablewhite J, Drummond A

    International journal of clinical practice 2018; e13300 doi:10.1111/ijcp.13300.

    PMID: 30507025
  12. 12

    Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease.

    Wang G, Xiong C, McDade EM, et al.

    Alzheimer's & dementia (New York, N. Y.) 2018; (4()):669-676 doi:10.1016/j.trci.2018.10.009.

    PMID: 30569014
  13. 13

    Association of BDNF Val66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease.

    Lim YY, Maruff P, Barthélemy NR, et al.

    JAMA neurology 2022; (79(3)):261-270 doi:10.1001/jamaneurol.2021.5181.

    PMID: 35099506
  14. 14

    γ-Secretase activity, clinical features, and biomarkers of autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analysis of the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS).

    Schultz SA, Liu L, Schultz AP, et al.

    The Lancet. Neurology 2024; (23(9)):913-924 doi:10.1016/S1474-4422(24)00236-9.

    PMID: 39074479
  15. 15

    Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN-TU-001 trial.

    McCullough A, Chen CD, Gordon BA, et al.

    Alzheimer's & dementia : the journal of the Alzheimer's Association 2025; (21(7)):e70347 doi:10.1002/alz.70347.

    PMID: 40660741
  16. 16

    A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.

    Salloway S, Farlow M, McDade E, et al.

    Nature medicine 2021; (27(7)):1187-1196 doi:10.1038/s41591-021-01369-8.

    PMID: 34155411
  17. 17

    Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.

    Rabinovici GD, Knopman DS, Arbizu J, et al.

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2025; (66(Suppl 2)):S5-S31 doi:10.2967/jnumed.124.268756.

    PMID: 39778970
  18. 18

    Head-to-head comparison of leading blood tests for Alzheimer's disease pathology.

    Schindler SE, Petersen KK, Saef B, et al.

    Alzheimer's & dementia : the journal of the Alzheimer's Association 2024; (20(11)):8074-8096 doi:10.1002/alz.14315.

    PMID: 39394841
  19. 19

    Different rates of cognitive decline in autosomal dominant and late-onset Alzheimer disease.

    Buckles VD, Xiong C, Bateman RJ, et al.

    Alzheimer's & dementia : the journal of the Alzheimer's Association 2022; (18(10)):1754-1764 doi:10.1002/alz.12505.

    PMID: 34854530

This page provides educational information on building a care team for Autosomal Dominant Alzheimer Disease (ADAD). It is for informational purposes only and does not replace professional medical advice, diagnosis, or treatment.

Get notified when new evidence is published on Early-onset autosomal dominant Alzheimer disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.